Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Progress in Myeloma — A Monoclonal Breakthrough

Rajkumar, S. Vincent, Kyle, Robert A. · 2016 · New England Journal of Medicine

Abstract

In the past decade, we have witnessed more progress in the treatment of multiple myeloma than any other cancer. An improved understanding of disease pathogenesis coupled with biomarker discovery has led to a new disease definition.1 The pronounced depth of response that is possible with new treatments has prompted the development of the assessment of minimal residual disease.2 More importantly, overall survival among patients with myeloma has more than doubled, which is attributable in large part to the effective incorporation of lenalidomide (an immunomodulatory, cereblon-binding drug) and bortezomib (a first-in-class proteasome inhibitor) into the modern therapy for the disease.In . . .

Overview

Integrity signals

Registry

Crossref · 10.1056/nejme1609835

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 10 references

Cited by

See all 40

Metadata

Authors
Rajkumar, S. V., & Kyle, R. A.
Affiliations
Mayo Clinic (US)
Venue
New England Journal of Medicine
Published
2016-10-06
Volume
375
Issue
14
Pages
1390-1392
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2528979204
Cited by
40
References
10
Citations by year
2026: 1 · 2024: 3 · 2023: 2 · 2022: 3 · 2021: 4 · 2020: 3 · 2019: 5 · 2018: 9 · 2017: 8 · 2016: 2
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords
multiple myeloma, lenalidomide, bortezomib, immunomodulators, proteasome inhibitors, minimal residual disease, pathogenesis, biomarkers, overall survival, monoclonal antibodies
MeSH terms
Antibodies, Monoclonal, Humans, Multiple Myeloma, Paraproteinemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Progress in Myeloma — A Monoclonal Breakthrough. https://app.cochat.ai/papers/10.1056/nejme1609835
The paper
Rajkumar, S. V., & Kyle, R. A. (2016). Progress in Myeloma — A Monoclonal Breakthrough. New England Journal of Medicine. https://doi.org/10.1056/nejme1609835

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.